StockData
Evolus, Inc. logo

Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$6.63−0.33 (-4.74%)

Close on Nov 16, 2026Market cap $437.91MP/E –Yield –

Evolus r&d expenses

Research and development expenses are spending on new products and technology.

Evolus's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.66M, up 9.8% year over year. For fiscal 2025 it was $9.58M, up 4.4% from the year before. The highest annual figure on record is $9.58M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.58M+4.4%
FY2024Dec 31, 2024$9.17M+39.9%
FY2023Dec 31, 2023$6.56M+38.3%
FY2022Dec 31, 2022$4.74M+129.7%
FY2021Dec 31, 2021$2.06M+19.9%
FY2020Dec 31, 2020$1.72M-56.7%
FY2019Dec 31, 2019$3.97M-38.8%
FY2018Dec 31, 2018$6.49M-3.0%
FY2017Dec 31, 2017$6.69M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.89M+3.0%
Q1 FY2026Mar 31, 2026$2.24M+1.3%
Q4 FY2025Dec 31, 2025$3.48M+43.3%
Q3 FY2025Sep 30, 2025$2.05M-11.6%
Q2 FY2025Jun 30, 2025$1.84M-21.8%
Q1 FY2025Mar 31, 2025$2.21M+6.4%
Q4 FY2024Dec 31, 2024$2.43M+2.1%
Q3 FY2024Sep 30, 2024$2.31M+45.8%
Q2 FY2024Jun 30, 2024$2.35M+94.5%
Q1 FY2024Mar 31, 2024$2.08M+50.5%
Q4 FY2023Dec 31, 2023$2.38M+76.6%
Q3 FY2023Sep 30, 2023$1.59M+15.3%
Q2 FY2023Jun 30, 2023$1.21M-22.1%
Q1 FY2023Mar 31, 2023$1.38M+195.1%
Q4 FY2022Dec 31, 2022$1.35M+218.7%
Q3 FY2022Sep 30, 2022$1.38M+357.1%
Q2 FY2022Jun 30, 2022$1.55M+210.6%
Q1 FY2022Mar 31, 2022$468.00K-44.4%
Q4 FY2021Dec 31, 2021$423.00K-41.2%
Q3 FY2021Sep 30, 2021$301.00K-14.0%
Q2 FY2021Jun 30, 2021$499.00K+244.1%
Q1 FY2021Mar 31, 2021$841.00K+65.9%
Q4 FY2020Dec 31, 2020$719.00K+72.0%
Q3 FY2020Sep 30, 2020$350.00K-49.5%
Q2 FY2020Jun 30, 2020$145.00K-71.5%
Q1 FY2020Mar 31, 2020$507.00K-78.5%
Q4 FY2019Dec 31, 2019$418.00K-64.7%
Q3 FY2019Sep 30, 2019$693.00K-64.9%
Q2 FY2019Jun 30, 2019$509.00K-69.1%
Q1 FY2019Mar 31, 2019$2.35M+40.2%
Q4 FY2018Dec 31, 2018$1.18M-2.0%
Q3 FY2018Sep 30, 2018$1.98M+34.9%
Q2 FY2018Jun 30, 2018$1.65M+20.7%
Q1 FY2018Mar 31, 2018$1.68M-36.7%
Q4 FY2017Dec 31, 2017$1.21M–
Q3 FY2017Sep 30, 2017$1.47M–
Q2 FY2017Jun 30, 2017$1.37M–
Q1 FY2017Mar 31, 2017$2.65M–

More Evolus figures

See a number that looks wrong?